Haemonetics (HAE) vs Envista (NVST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed Envista (NVST) over the past year, gaining 106.5% versus a gain of 12.8%. Over five years, HAE leads with a +45.5% price change compared with -40.5% for NVST. Haemonetics is the larger company by market cap ($5.39 billion vs $3.62 billion), about 1.5 times the size, while Envista is growing revenue faster (+8.3% vs -2.0%).
On valuation, Envista trades at a lower forward P/E (13.5x vs 20.5x for Haemonetics). Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus 1.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | NVST |
|---|---|---|
| Share price | $118.54 | $22.53 |
| Market cap | $5.39B | $3.62B |
| 1-day change | +16.55% | -2.24% |
| YTD return | +26.90% | +6.13% |
| 1-year return | +106.48% | +12.83% |
| 5-year return | +45.49% | -40.50% |
| P/E ratio (TTM) | 57.27 | 38.84 |
| Forward P/E | 20.52 | 13.54 |
| EPS (TTM) | $2.07 | $0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $2.72B |
| Revenue growth (YoY) | -1.97% | +8.32% |
| Net income (latest FY) | $97.31M | $47.00M |
| Gross margin | 59.04% | 54.67% |
| Operating margin | 11.75% | 7.95% |
| Net margin | 7.29% | 1.73% |
| 52-week high | $120.72 | $30.42 |
| 52-week low | $48.17 | $18.77 |
| Distance from 52-week high | -1.81% | -25.95% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -5.94% | +31.81% |
| Average volume | 678.94K | 2.81M |
| Shares outstanding | 45.50M | 160.62M |
| Employees | 3,009 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed NVST by 93.6 percentage points over the past year.
- Haemonetics trades at a higher earnings multiple (57.3x vs 38.8x trailing P/E).
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus 1.7 cents for Envista.
- Envista grew revenue faster in its latest fiscal year (+8.32% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Envista
NVST stock →Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Health Care · Medical/Dental Instruments · 12,000 employees
HAE vs NVST FAQ
Which is bigger, Haemonetics or Envista?
Haemonetics (HAE) is larger, with a market capitalization of $5.39B compared with $3.62B for Envista (NVST).
Which stock has performed better over the past year, HAE or NVST?
HAE returned +106.48% over the past 12 months, compared with +12.83% for NVST (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or NVST?
NVST has the lower trailing P/E at 38.8, versus 57.3 for HAE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and Envista in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.